Eva Medtec
Early Stage
Automated Lymphatic Therapy (ALT) Technology
Overview
Raised: $118,614
Total Commitments ($USD)
Platform
StartEngine
Start Date
12/20/2022
Close Date
03/20/2023
Min. Goal
$9,999
Max. Goal
$1,235,000
Min. Investment
$299
Security Type
Equity - Common
Series
Seed
Funding Type
RegCF
Price Per Share
$1.49
Pre-Money Valuation
$11,030,000
Rolling Commitments ($USD)
Status
Active
Reporting Date
02/01/2023
Days Remaining
47
% of Min. Goal
1,186%
% of Max. Goal
10%
Likelihood of Max
Avg. Daily Raise
$2,758
# of Investors
32
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Location
Bloomington, Minnesota
Industry
Healthcare & Pharmaceuticals
Tech Sector
Medtech
Distribution Model
B2C
Margin
Low
Capital Intensity
High
Eva Medtec, with a valuation of $11,030,000, is raising funds on Startengine. They make it possible for anyone to experience the benefits of automated lymphatic therapy with one simple, at-home system. Eva Medtec is targeting the $4B Pain Management Devices market. They have created and manufactured Neuroglide™, an over the counter, FDA-cleared medical device engineered to automate and emulate manual lymphatic drainage (MLD) therapy. Irene Waldridge founded Eva Medtec in 2016. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,234,999. The campaign proceeds will be used for company employment, inventory, working capital and clinical studies.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$68,149 |
$0 |
|
COGS |
$75,458 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-885,098 |
$-794,843 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$20,486 |
$253,766 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$473,507 |
$603,758 |
|
Short-Term Debt |
$147,154 |
$120,854 |
|
Long-Term Debt |
$50,000 |
$31,214 |
|
Total Liabilities |
$197,154 |
$152,068 |
Financials as of: 12/20/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
